-
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up2023 Annals of Oncology article Medicine Lung Cancer Treatments and Mutations Open access cited by 1 patent
Lizza E.L. Hendriks, Keith M. Kerr, Jessica Menis, Tony S.K. Mok, Ursula Nestle, Antonio Passaro, +6 more
854citations -
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer2022 Annals of Oncology article Medicine PARP inhibition in cancer therapy Open access cited by 1 patent
Charles E. Geyer, Judy Ellen Garber, Richard D. Gelber, Greg Yothers, L. Ross, Priya Rastogi, +90 more
473citations -
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline2022 Annals of Oncology article Biochemistry, Genetics and Molecular Biology BRCA gene mutations in cancer Open access
Cristiana Sessa, Judith Balmañà, Sharon L. Bober, Maria João Cardoso, N. Colombo, Giuseppe Curigliano, +12 more
296citations -
Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges2020 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Joerg Heil, Henry M. Kuerer, André Pfob, Gaiane Margishvili Rauch, Hans‐Peter Sinn, Michael Golatta, +1 more
236citations -
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial2021 Annals of Oncology article Biochemistry, Genetics and Molecular Biology BRCA gene mutations in cancer Open access cited by 1 patent
Alba Llop‐Guevara, Sibylle Loibl, Guillermo Javierre Villacampa, Valentina A. Vladimirova, Andreas Schneeweiß, Thomas Karn, +14 more
107citations -
Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study2022 Annals of Oncology article Pharmacology, Toxicology and Pharmaceutics Pharmacogenetics and Drug Metabolism Open access
Stefanie L. Groenland, Ruben A.G. van Eerden, Kim Westerdijk, Marinda Meertens, Stijn L.W. Koolen, Dirk Jan A. R. Moes, +12 more
82citations -
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)☆
Paolo Giovanni Casali, Axel Le Cesne, Andrés Poveda Velasco, Dusan Kotasek, Piotr Lukasz Rutkowski, Peter Hohenberger, +15 more
75citations -
Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial
Wobbe O. de Steur, Romy M. van Amelsfoort, H.H. Hartgrink, Hein Putter, Elma Meershoek‐Klein Kranenbarg, Nicole C.T. van Grieken, +13 more
69citations -
LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial2023 Annals of Oncology conference-abstract Medicine Pancreatic and Hepatic Oncology Research Open access
Bas Groot Koerkamp, Quisette P. Janssen, Jacob L. van Dam, Bert A. Bonsing, H. J. M. Bos, Koop P Bosscha, +14 more
59citations -
LBA75 Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): A phase-III stepped-wedge cluster randomised trial2023 Annals of Oncology conference-abstract Medicine Esophageal Cancer Research and Treatment Open access
Berend J. van der Wilk, Ben M. Eyck, Bas P. L. Wijnhoven, Sjoerd M. Lagarde, Camiel Rosman, Bo Jan Noordman, +14 more
52citations